Therapeutic phlebotomy.
作者信息
Zubair Abba
机构信息
Department of Laboratory Medicine and Pathology Mayo Clinic Jacksonville FL.
出版信息
Clin Liver Dis (Hoboken). 2014 Dec 9;4(5):102-106. doi: 10.1002/cld.408. eCollection 2014 Nov.
Abstract
摘要
相似文献
1
Therapeutic phlebotomy.治疗性放血术
Clin Liver Dis (Hoboken). 2014 Dec 9;4(5):102-106. doi: 10.1002/cld.408. eCollection 2014 Nov.
2
The effect of therapeutic phlebotomy for hemochromatosis on non-suicidal self-injury: A case report.治疗性放血疗法对血色素沉着症患者非自杀性自伤行为的影响：一例报告
Int J Psychiatry Med. 2019 Jan;54(1):74-79. doi: 10.1177/0091217418791451. Epub 2018 Jul 30.
3
Obesity hypoventilation syndrome in a 12-year-old child requiring therapeutic phlebotomy: case report and review of the literature.一名12岁儿童肥胖低通气综合征需进行治疗性放血：病例报告及文献综述
Pediatr Int. 2014 Dec;56(6):e99-e101. doi: 10.1111/ped.12451.
4
A survey of phlebotomy among persons with hemochromatosis.一项关于血色素沉着症患者静脉穿刺采血的调查。
Transfusion. 1999 Jun;39(6):651-6. doi: 10.1046/j.1537-2995.1999.39060651.x.
5
A comparison of the results obtained with traditional phlebotomy and with therapeutic erythrocytapheresis in patients with erythrocytosis.比较传统放血疗法和治疗性红细胞单采术在红细胞增多症患者中的疗效。
Blood Transfus. 2007 Jan;5(1):20-3. doi: 10.2450/2007.0010-06.
6
Ferroportin Disease Caused by a Heterozygous Variant p.Cys326Phe in the SLC40A1 Gene and the Efficacy of Therapeutic Phlebotomy in Children.由SLC40A1基因杂合变异p.Cys326Phe引起的铁转运蛋白病及儿童治疗性放血的疗效
J Pediatr Hematol Oncol. 2019 Jul;41(5):e325-e328. doi: 10.1097/MPH.0000000000001301.
7
Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis.血色素沉着症中铁过载的严重程度：诊断前自愿献血的影响。
Transfusion. 2001 Jan;41(1):123-9. doi: 10.1046/j.1537-2995.2001.41010123.x.
8
Ensuring donor safety: is venesecting therapeutic donors to haemoglobin levels below Blood Service guidelines safe?确保供者安全：将治疗性献血者的血红蛋白水平降至低于血库指南安全吗？
Vox Sang. 2020 May;115(4):288-292. doi: 10.1111/vox.12900. Epub 2020 Feb 20.
9
Unexplained Hematocrit Increase after Therapeutic Phlebotomy in a Patient with Marked Erythrocytosis.一名显著红细胞增多症患者治疗性放血后出现原因不明的血细胞比容升高。
Case Rep Hematol. 2022 Aug 11;2022:5018388. doi: 10.1155/2022/5018388. eCollection 2022.
10
Revisiting the impact of serial therapeutic phlebotomy in polycythaemia on laboratory and clinical parameters using a fixed interval and fixed volume protocol.采用固定间隔和固定血量方案重新审视系列治疗性放血术对真性红细胞增多症实验室及临床参数的影响。
Transfus Clin Biol. 2023 Feb;30(1):63-68. doi: 10.1016/j.tracli.2022.07.003. Epub 2022 Jul 11.
引用本文的文献
1
Clinical Advantages of Phlebotomy: An Umbrella Review of Meta-Analyses.放血疗法的临床优势：Meta分析的概述性综述
Iran J Public Health. 2024 Dec;53(12):2683-2693.
2
Dysarthria and Altered Mental Status Following Electroconvulsive Therapy (ECT) in a Patient With Polycythemia Vera: A Case Report.真性红细胞增多症患者接受电休克治疗（ECT）后出现构音障碍和精神状态改变：一例报告
Cureus. 2024 Nov 18;16(11):e73941. doi: 10.7759/cureus.73941. eCollection 2024 Nov.
3
Ferroptosis as a potential connection between schizophrenia and metabolic dysfunction-associated steatotic liver disease - a narrative review.铁死亡作为精神分裂症与代谢功能障碍相关脂肪性肝病之间的潜在联系——一篇叙述性综述
Postep Psychiatr Neurol. 2024 Sep;33(3):178-187. doi: 10.5114/ppn.2024.142136. Epub 2024 Sep 6.
4
Clinical applications of therapeutic phlebotomy.治疗性放血的临床应用
J Blood Med. 2016 Jul 18;7:139-44. doi: 10.2147/JBM.S108479. eCollection 2016.
本文引用的文献
1
The ferroportin disease.铁转运蛋白病
Clin Liver Dis (Hoboken). 2014 May 27;3(5):98-100. doi: 10.1002/cld.340. eCollection 2014 May.
2
Hereditary hemochromatosis types 1, 2, and 3.1型、2型和3型遗传性血色素沉着症。
Clin Liver Dis (Hoboken). 2014 May 27;3(5):96-97. doi: 10.1002/cld.339. eCollection 2014 May.
3
Delayed choroidal and retinal blood flow in polycythaemia vera patients with transient ocular blindness: a preliminary study with fluorescein angiography.真性红细胞增多症伴短暂性失明患者脉络膜和视网膜血流延迟：荧光素血管造影初步研究
Br J Haematol. 2013 Jun;161(5):745-747. doi: 10.1111/bjh.12290. Epub 2013 Mar 15.
4
Use of blood therapeutically drawn from hemochromatosis patients. Council on Scientific Affairs, American Medical Association.治疗性使用从血色素沉着症患者身上抽取的血液。美国医学协会科学事务委员会。
Transfusion. 1999 Sep;39(9):1018-26. doi: 10.1046/j.1537-2995.1999.39091018.x.
5
Management of hemochromatosis. Hemochromatosis Management Working Group.血色素沉着症的管理。血色素沉着症管理工作组。
Ann Intern Med. 1998 Dec 1;129(11):932-9. doi: 10.7326/0003-4819-129-11_part_2-199812011-00003.
6
Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.原发性血色素沉着症的肝硬化和非肝硬化患者的生存率及死亡原因
N Engl J Med. 1985 Nov 14;313(20):1256-62. doi: 10.1056/NEJM198511143132004.
7
Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.
Lancet. 1978 Dec 9;2(8102):1219-22. doi: 10.1016/s0140-6736(78)92098-6.
Zotero 插件